Amryt Pharma, a company focused on treatments for rare and orphan diseases, has named Jordi Casals as its new head of Europe, it was reported on Friday.

Taking responsibility for leading and developing Amryt's European operations, Casals' new role will see him initially concentrate on the sales growth of the company's commercial asset, Lojuxta, a treatment for adult patients with Homozygous Familial Hypercholesterolaemia.

Casal has more than 20 years' experience in the pharmaceutical and biotech industry and most recently worked for Aegerion Pharmaceuticals as a consultant, managing its commercial operations in the Iberia region. Prior to this, he worked for eight years at Alexion Pharmaceuticals, latterly as vice president commercial operations, Western Europe.